Policy | July 07, 2022
NHA announces successful onboarding of 1 lakh+ healthcare facilities
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth’s peptide customers.
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
Subscribe To Our Newsletter & Stay Updated
